Compare Novartis AG (NVS) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Value Index Fund ETF — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Vanguard Value Index Fund ETF trades at $219.8 (market cap $262.40B). The key difference: Novartis AG and Vanguard Value Index Fund ETF are close in size by market cap, and Novartis AG pays a 3.31% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| NVS | VTV | |
|---|---|---|
Market Cap | $268.57B | $262.40B |
Volume | 1,532,573 | 3,293,281 |
Sector | Health | — |
52-Week High | $168.62 | $227.51 |
52-Week Low | $121.80 | $182.86 |
Typical Hold Time | 82 Days | 142 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Vanguard Value ETF (VTV) trades at $218.21, down 0.35% on the day amid a bearish technical signal. The ETF shows neutral momentum oscillators but bearish moving averages, with key support at $217 and resistance at $219. Recent institutional buying by QRG Capital Management and Blue Edge Capital reflects confidence in value strategies, while news highlights VTV's 2.3% dividend yield and outperformance versus growth ETFs in 2026.
VTV offers exposure to large-cap value stocks with a low 0.03% expense ratio, appealing for income and stability. Risks include prolonged underperformance versus growth sectors and market rotation sensitivity. Analyst sentiment is mixed, balancing dividend appeal against broader market trends. The ETF remains a core holding for value-focused portfolios amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
